A Validated Quantitative Assay to Detect Occult Micrometastases by Reverse Transcriptase-Polymerase Chain Reaction of Guanylyl Cyclase C in Patients with Colorectal Cancer

Stephanie Schulz, Terry Hyslop, Janis Haaf, Christine Bonaccorso, Karl Nielsen, Matthew E. Witek, Ruth Birbe, Juan Palazzo, David Weinberg, and Scott A. Waldman

Abstract

Purpose: Guanylyl cyclase C (GCC), a receptor for bacterial diarrheagenic enterotoxins, may be a prognostic and predictive marker to detect occult micrometastases in patients undergoing staging for colorectal cancer. However, quantification of GCC expression in tissues by the quantitative reverse transcription-PCR (qRT-PCR) has not undergone analytic and clinicopathologic validation.

Experimental Design: A technique to quantify GCC mRNA in tissues employing RT-PCR was developed and validated employing external calibration standards of RNA complementary to GCC.

Results: GCC qRT-PCR exhibited reaction efficiencies >92%, coefficients of variations <5%, linearity > 6 orders of magnitude, and a limit of quantification of >25 copies of GCC cRNA. This assay confirmed that GCC mRNA was overexpressed by colorectal tumors from 41 patients, which correlated with increased GCC protein quantified by immunohistochemistry. Analyses obtained with 164 lymph nodes from patients free of cancer and 15 nodes harboring metastases established a threshold for metastatic disease of ~200 GCC mRNA copies/μg total RNA, with a sensitivity of 93% and specificity of 97%. GCC mRNA above that threshold was detected in 76 of 367 (21%) nodes free of disease by histopathology from 6 of 23 (26%) patients, suggesting the presence of occult micrometastases.

Conclusions: Quantifying GCC mRNA in tissues by RT-PCR employing external calibration standards is analytically robust and reproducible, with high clinicopathologic sensitivity and specificity. This validated assay is being applied to ~10,000 lymph nodes in a prospective trial to define the sensitivity of GCC qRT-PCR for staging patients with colorectal cancer.

Colorectal cancer is the third leading cause of cancer and the second leading cause of cancer-related mortality in the United States (1). The single most important prognostic and predictive determinant for the management of affected patients is the presence of metastatic tumor cells in regional lymph nodes (2, 3). Indeed, patients with metastases to regional lymph nodes have an increased risk of developing recurrent disease and receive adjuvant chemotherapy with well-defined efficacy (1–4). In contrast, patients with disease confined to the bowel wall generally have a reduced risk of developing recurrent disease and receive conservative management consisting of surgery and postoperative surveillance (1–5). However, up to 35% of patients with disease ostensibly confined to the intestine subsequently develop metastatic disease, presumably reflecting occult micrometastases in regional lymph nodes and other tissues that escape detection at the time of staging (6–8). Understaging likely reflects the limitations of current paradigms, including inadequate lymph node sampling (9, 10), inadequate sampling of tissues available for analysis (6–8), and limitations in analytic sensitivity of routine histopathology (6–8, 11). Unfortunately, failure to identify micrometastases can result in undertreatment of patients who might otherwise benefit from chemotherapy (6, 8, 9, 12).

These considerations underscore the unmet need for approaches to more accurately stage patients with colorectal cancer. In that context, an emerging paradigm in molecular diagnostics involves the detection of rare cancer cells employing sensitive amplification techniques and specific tumor markers (6–8). Indeed, the reverse transcription-PCR (RT-PCR) is a sensitive and specific method to quantify the expression of rare mRNA molecules in nucleic acids extracted from tissue...
specimens (13–16). This technique overcomes key limitations in current staging paradigms, including inadequate tissue sampling, because RNA can be extracted from the entire specimen and sampled analytically. Moreover, RT-PCR can detect a single cancer cell in $10^6$ to $10^7$ normal cells, improving detection sensitivities >4 orders of magnitude compared with histopathology, which detects a single cancer cell in ~$10^2$ normal cells (12–16).

Although amplification technologies have provided highly sensitive methods for cancer cell enumeration, the availability of tumor markers with sensitivities and specificities sufficient to reliably quantify occult colorectal cancer cells and to which amplification technologies can be applied have lagged (14). In that regard, guanylyl cyclase C (GCC) is the intestine-specific member of the particulate family of guanylyl cyclases (17). GCC is the receptor for the endogenous peptides guanylin and uroguanylin and diarrheagenic bacterial heat-stable enterotoxins. Canonical signaling by this family of proteins involves ligand-induced accumulation of intracellular cyclic guanosine 3',5'-monophosphate, which in intestinal epithelial cells regulates ionic conductances and fluid and electrolyte secretion, manifesting as diarrhea. Of significance, GCC is selectively expressed in apical membranes of intestinal epithelial cells from the duodenum to the rectum but not in tissues or tumors originating outside the gastrointestinal tract (18–20). Further, this receptor continues to be expressed after normal epithelial cells undergo neoplastic transformation and become colorectal cancer cells (19, 20). Moreover, GCC expression has been identified in every primary and metastatic colorectal tumor obtained from patients regardless of tumor grade or anatomic location (19–22). Thus, GCC may fulfill the criteria for a sensitive and specific prognostic and predictive marker for identifying occult colorectal micrometastases (12). Indeed, in a retrospective analysis, detection of GCC expression by qualitative RT-PCR in lymph nodes free of metastases by histopathology was highly associated with the development of recurrent colorectal cancer (23).

The foregoing suggests that quantitative RT-PCR (RT-PCR) for GCC might enumerate clinically significant occult tumor cells in lymph nodes of patients undergoing staging for colorectal cancer. In that context, GCC qRT-PCR is being examined in a multicenter prospective clinical trial to accurately identify occult micrometastases that predict clinical outcomes in patients with colorectal cancer (12). Of significance, few, if any, molecular markers have undergone rigorous analytic and clinicopathologic validation for detecting rare tumor cells in otherwise normal tissues by qRT-PCR. Here, analytic and clinicopathologic validation of the assay for quantifying GCC mRNA by RT-PCR employed in that prospective clinical trial is described. The assay, which quantifies GCC mRNA in tissues by comparison with a standard curve amplifying RNA complementary to GCC, exhibits high analytic sensitivity, with a lower limit of quantification of 25 copies of GCC mRNA, and is robust, with a coefficient of variation (CV) of <5%. This assay confirmed that GCC is overexpressed by primary colorectal tumors compared with matched normal adjacent mucosa (18). Moreover, this assay exhibited a nominal sensitivity of 93% when applied to lymph nodes harboring colorectal metastases identified by histopathology (true positives) and a specificity of >97% employing lymph nodes from patients who did not have colorectal cancer (true negatives). Importantly, GCC qRT-PCR revealed that 76 of 367 (~21%) lymph nodes free of tumor cells by histopathology from 6 of 23 (26%) patients with colorectal cancer may harbor occult micrometastases.

**Materials and Methods**

**Surgical samples.** Tissue samples were obtained from patients undergoing surgery at Thomas Jefferson University Hospital under a protocol approved by the institutional review board (control 01.0823). A pathologist (R.B. or J.P.) reviewed all H&E-stained slides to confirm the diagnosis and ensure the presence of representative tissues. All diagnoses in this study were established using current standard criteria, and specimens included 10 small intestines, 85 normal colonic mucosa, 26 adenomas, 63 colorectal adenocarcinomas, and 546 lymph nodes. Of 41 colorectal cancer patients, 23 (56%) were female and 13 (44%) were male, with an average age of 68 years (31–95 years). In these patients, tumors were recovered from the cecum (7%), ascending (37%), transverse (7%), descending (2%), sigmoid (35%), and rectum (12%). The majority (80%) of tumors were moderately differentiated, with a minority either well (10%) or poorly (10%) differentiated. Specimens of colon tumor and histologically normal mucosa were dissected free of underlying muscle and fat. Colonic lymph nodes were dissected using a clean set of surgical instruments and bisected. Half of each lymph node was submitted for standard histopathologic examination. Tonsils were obtained from children undergoing routine tonsillectomy. All samples were either snap-frozen or frozen in RNA Later (Ambion, Austin, TX).

**RNA extraction.** RNA was extracted from tissues by a modification of the acid guanidinium thiocyanate-phenol-chloroform extraction method (19, 23). Briefly, individual tissues were pulverized in 1.0 mL Tri-Reagent (Molecular Research Center, Cincinnati, OH) with 12 to 14 sterile 2.5-mm zirconium beads in a bead mill (Biospec, Bartlesville, OK) for 1 to 2 minutes. Phase separation was done with 0.1 mL bichloroacetic acid, and the aqueous phase was reextracted with 0.5 mL chloroform. RNA was precipitated with isopropanol and washed with 75% ethanol. Linear acrylamide (50 µg) was included when lymph nodes were <1 mm in diameter. Air-dried RNA was dissolved in water, concentration determined by spectrophotometry, and stored at –80°C.

**Synthesis of cRNA standards.** Bluescript plasmids containing ~1.5 kb of the human GCC cDNA, corresponding to the extracellular ligand-binding domain (Bluescript SK, Stratagene, La Jolla, CA), or full-length human β-actin cDNA (Bluescript KS, Stratagene) were linearized with BamHI or XhoI, respectively. Linearized plasmids were used as templates for in vitro transcription (T7 Ribonmax kit, Promega, Madison, WI). Template DNA was removed by DNase I digestion, and the in vitro transcripts were purified on RNeasy columns (Qiagen, Valencia, CA). Concentrations of cRNA were determined by spectrophotometry, and GCC and β-actin copy number was calculated. Standards were diluted to 1 × 10^5 copies/µL and stored at –80°C.

**Quantitative RT-PCR.** The EZ RT-PCR kit (Applied Biosystems, Foster City, CA) was employed to amplify GCC mRNA from total RNA in a 50 µL reaction. Optical strip tubes were used for all reactions, which were conducted in an ABI 7000 Sequence Detection System (Applied Biosystems). In addition to the kit components (50 mmol/L Bicine (pH 8.2); 115 mmol/L KOAc; 10 µmol/L EDTA; 60 µmol/L ROX; 8% glycerol; 3 mmol/L Mg(OAc)2; 300 µmol/L each of dATP, dCTP, and dTTP; 600 µmol/L diUTP; 0.5 unit uracil N-glycosylase; 5 units Tth DNA polymerase), the reaction master mix contained 900 nmol/L each of forward (ATTCATAGGATCTTTTCAATGACCA) and reverse (CGTCAAGAACAGGACATTITTTTCAATGACCA) primers, 200 µmol/L Taqman probe (FAM-TACTTGAGCAGATTGTCACAGCCTCTG-TAMBA), and 1 µg RNA template or a known amount of cRNA standard. β-Actin was amplified using similar conditions, except that forward (CCA-CACCTTGGCCCCATCTACCC) and reverse (AGGATCTCCATGAGTCTGAGT-CAGTCA) primers were 300 nmol/L each, whereas the Taqman probe

---

*Clin Cancer Res 2006;12(15) August 1, 2006 4546  www.aacrjournals.org*

Downloaded from clincancerres.aacrjournals.org on April 19, 2017. © 2006 American Association for Cancer Research.
described (18). Briefly, sections (5 μm) were incubated for 30 minutes in 3,3'-diaminobenzidine solution and then washed in deionized water, counterstained with Harris hematoxylin (SurgiPath, Richmond, IL), and dehydrated with xylene before mounting. In some experiments, purified rabbit antibodies were reincubated with the immunizing peptide before immunostaining to confirm that staining reflected specific interaction with GCC. Apical membrane staining was scored by two pathologists using a modified McCarty scale of +1 to +3 representing intensity of staining (27).

Statistical analyses. Mixed-effects linear models with random slope and intercepts per run within plate were used to assess linearity and variability of the assay standards across concentrations. Model variations included both fixed and random nominal effects of concentration to assess intra-assay and interassay variability. This variability is reported as the intra-assay and interassay CV defined as 100 × (SD / mean). Amplification slope efficiency is defined based on the slope of threshold cycle (Ct) versus log of concentration for each run: efficiency = 10(-1 / slope) - 1. Limit of detection of the assay is the lowest concentration at which fluorescence could be detected in >85% of the samples, whereas limit of quantitation is the lowest concentration at which fluorescence could be detected consistently in all samples.

Paired tumor and normal adjacent tissue samples were compared employing the Wilcoxon signed-rank test, the nonparametric equivalent of a paired t test, used here to determine overexpression or underexpression of GCC in paired patient samples. Associations of GCC copy number in tumor and normal adjacent tissue with Dukes stage, differentiation status, T stage, N stage, M stage, and grade of tumors were examined employing the Kruskal-Wallis test. This is a nonparametric equivalent of a one-way ANOVA, testing for differences in median gene expression across the categories investigated. The exact Kruskal-Wallis test was used to test the association of GCC apical staining intensity with tissue type. The "exact" form of the nonparametric one-way ANOVA is used due to small sample sizes in some categories of staining intensity. GCC expression was compared in tumors and matched normal adjacent tissue by quantifying differences in copy number and by the ratio of GCC in tumor and normal adjacent tissue (fold change). The sensitivity and specificity to detect tumor cells in lymph nodes employing GCC RT-PCR was determined employing lymph nodes harboring metastases detected by histopathology (true positives) and lymph nodes from patients with no evidence of colorectal cancer (true negatives). This analysis and the selection of the optimal cut point were completed using receiver operating characteristic analyses using logistic regression models followed by classification table analyses. In all analyses, two-sided tests were used and P < 0.05 was considered statistically significant.

Results

Validation of GCC cRNA calibration curve. Forward and reverse primers were designed that specifically recognize exons 6 and 7 of GCC, respectively, and produce a small (84-bp) amplicon. The 3’ end of the forward primer lies across the exon/intron boundary, effectively eliminating genomic DNA as a template for amplification. Purified cRNA standards, corresponding to the structurally unique extracellular ligand-binding domain of GCC, of defined concentrations, were employed to develop a calibration curve to quantify GCC mRNA in tissues. The performance characteristics of this assay were evaluated employing a series of replicate runs in which two standard curves, each derived from an independent master mix, were generated each day for 5 days for a total of 10 curves. At copy levels ≤100, samples were run in replicates of five, whereas all other standards (2 × 102-2 × 106 copies) were run in triplicate. Amplification reactions were exponential and there was no inverse relationship within initial cRNA copy number and Ct quantified by the change in fluorescence [ΔR(x); Fig. 1A]. Linear mixed model analysis of the relationship between Cc number and calibrator concentration (Fig. 1B) yielded an average intercept of 42.36 (95% confidence interval, 41.94-42.79), an average slope of –3.53 (95% confidence interval, –3.62 to –3.44), and a mean amplification slope efficiency of 92%. This assay was linear over the concentration range of 25 to 2 × 106 copies (Fig. 1B), with a limit of detection of <25 copies because >95% of samples at 25 copies were detected and a limit of quantitation of 25 copies because all samples were detected at that calibrator concentration. Overall plate-to-plate variability (CV) was 1%, whereas within-plate variability was <5% at all cRNA calibrator concentrations (Table 1).

Quantification of GCC by RT-PCR in biological matrices. Linear mixed model analysis of the relationship between threshold cycle number and the amount of calibration standards spiked into total RNA isolated from tonsils yielded an average intercept of 42.67 (95% confidence interval, 38.54-48.81), an average slope of –3.46 (95% confidence interval, –4.86 to –2.05).
and a mean amplification slope efficiency of 94%. This assay was linear over the concentration range of 50 to $2 \times 10^6$ copies with a limit of detection of <50 copies and a limit of quantitation of 50 copies. Moreover, linear mixed models of log (GCC copy number) estimated CVs of 53%, 45%, and 7% for repeat determinations of endogenous GCC expression in pathology-negative lymph nodes (background), pathology-positive lymph nodes (metastases), and primary tumors, respectively. Differences in variability in tumors and lymph nodes reflect the relative magnitude of GCC expression and the associated differences in variability at the low and high ends of calibration curves, respectively (Table 1). In the context of earlier studies validating quantification of tumor markers by RT-PCR, which showed CVs between specimens of 43% and >6,000%, the present observations show that GCC mRNA quantification by RT-PCR in relevant biological matrices employing external calibration standards is highly accurate, reproducible, and robust (28, 29).

Quantification of GCC mRNA in colorectal tumors and matched normal adjacent mucosa. GCC mRNA expression in 41 paired colorectal tumors and histologically normal adjacent mucosa was compared employing qRT-PCR and a GCC cRNA calibration curve. GCC mRNA expression varied ~2 orders of magnitude between individuals in both normal mucosa and colorectal tumors (Fig. 2A). Further, GCC mRNA was significantly overexpressed in tumors compared with matched normal adjacent mucosa from the same patient (Fig. 2A and B). Indeed, the median GCC mRNA copy number was ~2-fold higher in tumors compared with normal mucosa ($P = 0.002$, Wilcoxon signed-rank test). Overexpression of GCC mRNA correlated closely with increased expression of GCC protein in tumors compared with normal intestinal mucosa ($P < 0.001$, exact Kruskal-Wallis test; Fig. 2C; Table 2). Moreover, altered expression of GCC is an early event in neoplastic transformation in the colon because adenoma also significantly overexpress GCC (Fig. 2C; Table 2). Although most tumor samples were moderately differentiated and from patients with Dukes stage B or C disease, GCC mRNA copy number did not obviously correlate with tumor grade or stage.

GCC mRNA estimated by qRT-PCR correlates with the presence of metastatic colorectal cancer cells in lymph nodes. RNA was extracted from 546 lymph nodes from 48 patients, including nodes with confirmed metastases (true positives) and nodes from patients with nonmalignant diseases of the colon (adenoma, familial adenomatous polyposis, Crohn’s disease, and ulcerative colitis) and from sites outside the gastrointestinal
recurrent colorectal cancer (23). GCC mRNA in tissues, including regional lymph nodes, undetected by current staging paradigms. The inability to detect micrometastases likely reflects methodologic limitations of histopathology. Specifically, there is a relationship between the number of lymph nodes harvested and the sensitivity of histopathologic staging, and insufficient lymph node sampling contributes to the insensitivity of current staging paradigms (9, 10). Similarly, tumor cells may distribute asymmetrically within lymph nodes (30), and evaluation of a limited number (1-2) of 10-μm sections from lymph nodes that may be 1 cm may result in omission of key tissue sections from review. Moreover, there are limitations to the sensitivity of visual inspection, and 1 cancer cell in 200 normal cells is the lower limit for reliable histopathologic detection (11). The insensitivity of current staging paradigms presents a therapeutic dilemma to patients and physicians. Adjuvant chemotherapy has well-documented efficacy in patients with metastases in regional lymph nodes. A method that reliably quantifies tumor cells in lymph nodes that escape detection by histopathology could identify the subpopulation of patients who would benefit from adjuvant chemotherapy.

A paradigm emerging in molecular pathology is the detection of rare cells in tissues employing amplification technologies, such as RT-PCR, coupled with specific disease markers (6–8). This approach offers solutions to the methodologic limitations of histopathology. Thus, RNA can be isolated from the entire tissue specimen, permitting representative sampling of that tissue. Moreover, RT-PCR can amplify nucleic acid molecules 1010-fold and detect ~10 mRNA molecules, which translates to the detection of a single cancer cell in ~107 normal cells.

Although nucleic acid amplification has the sensitivity to detect rare tumor cells in tissues, the availability of ideal molecular markers that are highly specific for colorectal cancer have lagged. In that context, GCC, the receptor for the endogenous ligands guanylur and urouguanyl and diarrheagenic bacterial heat-stable enterotoxins, is expressed selectively by intestinal epithelial cells (6–8, 19, 20). This receptor continues to be expressed following neoplastic transformation and GCC mRNA has been identified in all colorectal tumors examined regardless of the anatomic location or grade of the tumor (6–8, 19–23). However, this receptor is not expressed by normal tissues or tumors originating outside the gastrointestinal tract (6–8, 19–23). The uniformity of expression of this receptor by human colorectal tumors and its absence from other human tissues and tumors suggests that this receptor may fulfill the criteria for a highly specific molecular marker for occult micrometastases (12). Indeed, in a retrospective analysis, GCC RT-PCR detected the presence of occult micrometastases in lymph nodes from ~50% of 21 patients with colorectal cancer, which correlated closely with the risk of developing tumor recurrence (23).

These observations suggest that GCC may have utility for detecting occult micrometastases in patients undergoing staging for colorectal cancer. However, an assay to quantify GCC mRNA in tissues by RT-PCR has not been developed or

Discussion

Generally, ~40% of patients with colorectal cancer have no evidence of disease in lymph nodes at the time of staging and are presumably cured by surgery (1). However, up to 30% of patients with stage A disease and 50% of those with stage B disease in some series develop metastases and ultimately die (2–4). Overall, ~50% of patients who have undergone surgery with curative intent suffer recurrent disease. Recurrence in patients who are ostensibly disease-free presumably reflects the presence of occult micrometastases in tissues, including regional lymph nodes, undetected by current staging paradigms. The inability to detect micrometastases likely reflects methodologic limitations of histopathology. Specifically, there is a relationship between the number of lymph nodes harvested and the sensitivity of histopathologic staging, and insufficient lymph node sampling contributes to the insensitivity of current staging paradigms (9, 10). Similarly, tumor cells may distribute asymmetrically within lymph nodes (30), and evaluation of a limited number (1-2) of 10-μm sections from lymph nodes that may be 1 cm may result in omission of key tissue sections from review. Moreover, there are limitations to the sensitivity of visual inspection, and 1 cancer cell in 104 normal cells is the lower limit for reliable histopathologic detection (11). The insensitivity of current staging paradigms presents a therapeutic dilemma to patients and physicians. Adjuvant chemotherapy has well-documented efficacy in patients with metastases in regional lymph nodes. A method that reliably quantifies tumor cells in lymph nodes that escape detection by histopathology could identify the subpopulation of patients who would benefit from adjuvant chemotherapy.

A paradigm emerging in molecular pathology is the detection of rare cells in tissues employing amplification technologies, such as RT-PCR, coupled with specific disease markers (6–8). This approach offers solutions to the methodologic limitations of histopathology. Thus, RNA can be isolated from the entire tissue specimen, permitting representative sampling of that specimen for analysis. Moreover, RT-PCR can amplify nucleic acid molecules 1010-fold and detect ~10 mRNA molecules, which translates to the detection of a single cancer cell in ~107 normal cells.

Although nucleic acid amplification has the sensitivity to detect rare tumor cells in tissues, the availability of ideal molecular markers that are highly specific for colorectal cancer have lagged. In that context, GCC, the receptor for the endogenous ligands guanylur and urouguanyl and diarrheagenic bacterial heat-stable enterotoxins, is expressed selectively by intestinal epithelial cells (6–8, 19, 20). This receptor continues to be expressed following neoplastic transformation and GCC mRNA has been identified in all colorectal tumors examined regardless of the anatomic location or grade of the tumor (6–8, 19–23). However, this receptor is not expressed by normal tissues or tumors originating outside the gastrointestinal tract (6–8, 19–23). The uniformity of expression of this receptor by human colorectal tumors and its absence from other human tissues and tumors suggests that this receptor may fulfill the criteria for a highly specific molecular marker for occult micrometastases (12). Indeed, in a retrospective analysis, GCC RT-PCR detected the presence of occult micrometastases in lymph nodes from ~50% of 21 patients with colorectal cancer, which correlated closely with the risk of developing tumor recurrence (23).

These observations suggest that GCC may have utility for detecting occult micrometastases in patients undergoing staging for colorectal cancer. However, an assay to quantify GCC mRNA in tissues by RT-PCR has not been developed or
undergone analytic or clinicopathologic validation. Here, a RT-PCR assay for quantifying GCC mRNA in tissues was developed employing GCC cRNA calibrator standards. This assay exhibited analytic characteristics that suggest its suitability for application to quantifying GCC mRNA in clinical samples. Thus, mean reaction efficiencies of this assay were >90%, which compares favorably with other validated qRT-PCR assays (29, 31). Additionally, the assay is extremely robust and can quantify GCC mRNA >6 orders of magnitude with interday and intraday variabilities <5%, reflecting a level of analytic precision superior to many validated analytic assays. Further, the assay is sensitive and can reliably quantify 25 copies of GCC mRNA. Moreover, the assay is unaffected by the biological matrix in which the target mRNA resides.

In addition to analytic performance, this assay exhibited superior clinicopathologic characteristics that suggest its utility for quantifying occult tumor cells in lymph nodes of patients undergoing staging for colorectal cancer. Thus, this assay quantified the presence of GCC in 100% of specimens of normal intestinal mucosa and colorectal tumor examined, confirming the uniformity of GCC expression in colorectal tumorigenesis (12, 18–20, 22). Further, application of this assay to 164 lymph nodes obtained from patients who do not have colorectal cancer (true negatives) established a working range of basal GCC expression. Importantly, the range of basal expression of GCC mRNA in true negative lymph nodes could be clearly differentiated from the range of expression of that analyte in lymph nodes harboring tumor metastases visualized by histopathology. Moreover, employing those results, receiver-operator analysis revealed that GCC qRT-PCR was 100%
sensitive and 97% specific for identifying metastatic colorectal cancer cells in lymph nodes, comparable with commercially available diagnostic tests. Taken together, the favorable analytic and clinicopathologic characteristics of the GCC qRT-PCR assay suggest its suitability for examining the utility of GCC as a marker for staging patients with colorectal cancer.

RT-PCR and immunohistochemistry confirmed overexpression of GCC in colorectal tumors compared with normal mucosa from patients (18). Increased expression in tumors underscores an emerging paradigm concerning the role of GCC in mechanisms underlying colorectal carcinogenesis. GCC signaling induced by its endogenous ligands guanylin and uroguanylin regulates the proliferation of intestinal epithelial cells by restricting transit through the cell cycle in the absence of apoptosis or necrosis (32, 33). Indeed, this signaling mechanism regulates the proliferation of epithelial cells along the crypt-villus axis in intestinal mucosa. Further, oral administration of uroguanylin suppresses adenoma formation in APCMin- mice, a murine model of intestinal carcinogenesis (34). Moreover, guanylin and uroguanylin are the genes most commonly lost during intestinal carcinogenesis in humans (35). Together, these observations suggest a model wherein GCC is a key regulator of epithelial cell proliferation along the crypt-villus axis whose dysregulation through loss of ligand expression contributes to hyperproliferation associated with neoplastic transformation (33). In that context, overexpression of GCC in tumors compared with normal mucosa reflects the plasticity of cellular compensatory responses to reduced autocrine/paracrine regulation of the cell cycle by GCC ligands, which invariably accompanies neoplastic transformation in the colon.

In summary, an assay to detect occult micrometastases, employing GCC, a specific marker for colorectal cancer cells, and qRT-PCR employing external calibration standards was developed. Analytic validation showed that this assay was robust, with high efficiency, minimum variability, high precision, and high sensitivity. In addition, clinicopathologic validation employing true positive and true negative lymph nodes showed that this assay discriminated lymph nodes free of disease from those harboring tumor cells, with high sensitivity and specificity. Importantly, applying this assay to lymph nodes from colorectal cancer patients, which were free of metastases by histopathology, suggested that a significant fraction of those patients harbor occult micrometastases. This assay will be applied to the analysis of ~10,000 lymph nodes in an ongoing prospective multi-institutional trial to define the sensitivity and specificity of GCC qRT-PCR for staging patients with colorectal cancer (12). Specifically, this trial will define the utility of GCC qRT-PCR to prospectively identify patients at increased risk for developing recurrent colorectal cancer who might otherwise benefit from receiving adjuvant chemotherapy. In that context, the clinicopathologic threshold established here for the presence of occult micrometastases of 200 copies, with a nominal sensitivity of 93% and a specificity of 97%.

**Table 3. GCC expression estimated by qRT-PCR in 546 lymph nodes from 48 patients**

<table>
<thead>
<tr>
<th>Lymph nodes</th>
<th>Median</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extraintestinal (n = 20)</td>
<td>&lt;50</td>
<td>&lt;50</td>
<td>95</td>
</tr>
<tr>
<td>Ulcerative colitis (n = 40)</td>
<td>&lt;50</td>
<td>&lt;50</td>
<td>255</td>
</tr>
<tr>
<td>Crohn’s disease (n = 34)</td>
<td>&lt;50</td>
<td>&lt;50</td>
<td>309</td>
</tr>
<tr>
<td>Adenoma (n = 23)</td>
<td>&lt;50</td>
<td>&lt;50</td>
<td>369</td>
</tr>
<tr>
<td>Familial adenomatous polyposis (n = 42)</td>
<td>&lt;50</td>
<td>&lt;50</td>
<td>186</td>
</tr>
<tr>
<td>Other cancers (n = 5)</td>
<td>&lt;50</td>
<td>&lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>Colorectal cancer Pathology (−), (n = 367)</td>
<td>85</td>
<td>&lt;50</td>
<td>86,178</td>
</tr>
<tr>
<td>Pathology (+), (n = 15)</td>
<td>1,183</td>
<td>&lt;50*</td>
<td>323,167</td>
</tr>
</tbody>
</table>

*Includes true negative lymph node inadvertently switched with true positive lymph node (see Results).
References

Clinical Cancer Research

A Validated Quantitative Assay to Detect Occult Micrometastases by Reverse Transcriptase-Polymerase Chain Reaction of Guanylyl Cyclase C in Patients with Colorectal Cancer

Stephanie Schulz, Terry Hyslop, Janis Haaf, et al.


Updated version  Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/12/15/4545

Cited articles  This article cites 34 articles, 17 of which you can access for free at: http://clincancerres.aacrjournals.org/content/12/15/4545.full.html#ref-list-1

Citing articles  This article has been cited by 13 HighWire-hosted articles. Access the articles at: /content/12/15/4545.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.